Tenders Are Invited For Completion Of A Non -Exclusive Discount Agreement According To Section 130A (8) Sgb ...

Work Detail

Contract Notice: Completion Of A Non -Exclusive Discount Agreement According To Section 130A (8) Sgb V For The Active Ingredient Erythropoietin Alpha, Atc B03xa01 For The Time 01.03.2023 - 28.02.2025 Pharmaceutical Products Short Description: Section 130A Paragraph 8 Sgb V Enables Health Insurance Companies And Pharmaceutical Companies To Close Framework Discount Contracts Via The Drugs Submitted At The Expense Of The Statutory Health Insurance Companies. With Regard To The Relevant Legal Regulations On The Awarding Of Public Orders, There Is A Regular Process Of Active Ingredient, Formal Award Procedures According To The Regulations Of The 4Th Part Of The Gwb Through Dak Health. For Medicines To Be Named By The Bidder In Appendix 2 To The Contract To The Above. Active Ingredient Erythropoietin Alpha, Atc B03xa01, Intends To Conclude Dak Health Until The Entry Into Force Of New Pharmaceutical Discount Contracts With All Interested Pharmaceutical Companies As Possible. A Discount Contract I.R.D. The Active Ingredient Comes Into Force On 01.03.2023 For The First Time And Ends On February 28, 2025. It Ends Automatically With The Entry Into Force Of The Exclusive Contract. Deadline For Submission: 20250105 12:00 Type Of Buyer: Body Governed By Public Law Type Of Contract: Supplies Type Of Procedure: Open Procedure Regulation: European Union Type Of Bid: Submission For All Lots Award Criteria: Lowest Price [Disclaimer: The Above Text Is Machine Translated. For Accurate Information Kindly Refer The Original Document.] Tender Link : Https://Ted.Europa.Eu/Udl?Uri=Ted:Notice:036390-2023:Data:En:Html

Contact Information

Other Detail